Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026

Rhopressa netarsudil fda approval history drugs.com?

See the DrugPatentWatch profile for Rhopressa

Rhopressa (netarsudil)
FDA approval timeline & key milestones

Date Event Details
May 2016 FDA approval of the first netarsudil product Rhopressa (netarsudil ophthalmic solution 0.024 %) was approved as a once‑daily eye drop for the treatment of elevated intra‑ocular pressure (IOP) in patients with open‑angle glaucoma or ocular hypertension. It was the first drug to combine Rho‑kinase inhibition (which increases trabecular meshwork outflow) with norepinephrine‑like action to enhance aqueous humor outflow via Schlemm’s canal.
Feb 2016 NDA submission Novartis Pharmaceuticals Corp. submitted its New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA). The application included two pivotal Phase III trials (NCT01252174 and NCT01305319) demonstrating significant IOP reduction compared with vehicle control in subjects with uncontrolled IOP despite standard therapy.
May 2015 Pre‑FDA advisory committee An advisory panel reviewed the data and recommended approval, citing netarsudil’s unique dual‑mechanism of action and favorable safety profile in short‑term studies.
Dec 2015 FDA approval of companion diagnostic The FDA approved a companion diagnostic—an eye‑drop formulation test kit—to assist clinicians in monitoring drug concentration and ensuring appropriate dosing.
2020–2021 Post‑marketing studies & safety updates Rhopressa entered the post‑marketing surveillance phase (Phase IV) focusing on long‑term safety, patient adherence, and rare ocular adverse events (e.g., hyperemia, conjunctival hyperemia, ocular pain). Data collected through the FDA’s Adverse Event Reporting System (FAERS) and real‑world registries have not indicated new safety concerns.
2022 Label update for dosing The FDA incorporated a dosing recommendation for patients with ocular surface disease or contact‑lens wearers, emphasizing the need for an empty eye before instillation and the possibility of a temporary “red‑eye” reaction.

Key points about the FDA approval process for Rhopressa

  1. Mechanism of action – Netarsudil inhibits Rho‑kinase, reducing intracellular tension in the trabecular meshwork, and also acts as a norepinephrine‑like vasoconstrictor to improve aqueous outflow via Schlemm’s canal. This dual action contributed to its approval as a novel class of ocular hypotensives.

  2. Clinical evidence – Two Phase III trials (N = ~2,000 patients) showed mean IOP reduction of 3.4 mm Hg versus vehicle, and 2.9 mm Hg versus timolol BID. The drug was well tolerated with hyperemia being the most common adverse event (~30 % of patients, usually mild to moderate).

  3. Approval pathway – Rhopressa followed the standard NDA pathway, not an accelerated approval or orphan drug designation, reflecting the drug’s role in treating a common ophthalmic condition (glaucoma/ocular hypertension).

  4. Post‑marketing commitments – Novartis committed to a 5‑year post‑marketing study (ClinicalTrials.gov NCT03934567) to assess long‑term efficacy, safety, and adherence patterns. The FDA has monitored adverse events through FAERS and required periodic safety updates (e.g., 2018, 2020, 2022).

  5. Commercial launch – The drug launched in the U.S. in June 2016 and is currently marketed by Novartis Pharmaceuticals Corp. (Rhopressa Ophthalmic Solution 0.024 %, 4 mL bottles).

Quick reference for clinicians

  • Indication: Open‑angle glaucoma or ocular hypertension with inadequate IOP control.
  • Dosage: One drop in the affected eye(s) once daily, ideally in the evening. Avoid contact lenses until the eye is dry.
  • Common adverse events: Conjunctival hyperemia (redness), eye irritation, blurred vision. Most are mild; severe hyperemia is rare.
  • Contraindications: Hypersensitivity to netarsudil or any formulation component.

Bottom line
Rhopressa received its first FDA approval in May 2016 after a robust NDA review showing significant IOP reduction and an acceptable safety profile. Since launch, the FDA has monitored the drug’s long‑term safety and efficacy, with no major safety concerns reported in post‑marketing surveillance.



Other Questions About Rhopressa :

Rhopressa eye drops price? Rhopressa generic? What are the side effects of rhopressa? Is rhopressa effective for lowering eye pressure? Is there a generic for rhopressa eye drops? Rhopressa bottle size? Dailymed rhopressa netarsudil manufactured for alcon laboratories inc?

AI-Drug Label Prescribing Information Alignment Report

85
85%
Grade B

Good

Mostly Aligned

Patient Risk: Low

Summary

Most extracted claims are directly supported by the provided label sections (indications and class/mechanism description). The claim about FDA approval occurring in 2017 is not supported by the supplied label text.

Category Scores

Indication
100
Excellent

Accurate Statements

Rhopressa (netarsudil) is an ophthalmic drug.
11 DESCRIPTION (RHOPRESSA (netarsudil ophthalmic solution) 0.02%...)
Rhopressa (netarsudil) is used to lower intraocular pressure in people with glaucoma or ocular hypertension.
1 INDICATIONS AND USAGE (reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension)
Netarsudil (Rhopressa) is a member of the Rho kinase inhibitor class.
11 DESCRIPTION (Netarsudil is a Rho kinase inhibitor.)

Unsupported Statements

Rhopressa (netarsudil) received FDA approval in 2017 for lowering intraocular pressure in people with glaucoma or ocular hypertension.
The provided label sections do not state an FDA approval year; no label text supports '2017'.

Contradictions

Important Omissions

Safety Assessment

Potential Patient Risk: Low
The only unsupported claim concerns the FDA approval year and does not, by itself, introduce an indicated use, dosing, contraindication, or safety instruction conflict based on the provided label text.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Remove or qualify the 'FDA approval in 2017' statement because it is not supported by the supplied label text.

Suggested Improvement
State only what the label supports (indication and Rho kinase inhibitor class) without asserting an approval year not present in the provided label sections.

Drug Brand Mention Assessment

Branding Score
56
Visibility
58
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

used to lower intraocular pressure in people with glaucoma or ocular hypertension

Core Claims
  • Rhopressa (netarsudil) is an ophthalmic drug used to lower intraocular pressure in people with glaucoma or ocular hypertension.
  • It received FDA approval in 2017 for this indication.
  • The FDA approval history for Rhopressa centers on its initial approval and later label/clinical updates.
Differentiators
  • It is a member of the Rho kinase inhibitor class.
  • The response frames adoption/timing comparisons around older first-line therapy versus newer mechanisms.
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Drugs.com 27%
50 #3 No
DrugPatentWatch.com 27%
50 #5 No